» Articles » PMID: 31145876

Hepatitis C Disease Burden and Strategies for Elimination by 2030 in Brazil. A Mathematical Modeling Approach

Abstract

Introduction And Aim: Hepatitis C is a key challenge to public health in Brazil. The objective of this paper was to describe the Brazilian strategy for hepatitis C to meet the 2030 elimination goal proposed by World Health Organization (WHO).

Methods: A mathematical modeling approach was used to estimate the current HCV-infected Brazilian population, and to evaluate the relative costs of two different scenarios to address HCV disease burden in Brazil: (1) if no further changes are made to the HCV treatment program in Brazil; (2) where the WHO targets for 2030 elimination are met through diagnosis and treatment efforts peaking before 2024.

Results: An anti-HCV prevalence of 0.53% was calculated for the total population. It was estimated that the number of HCV-RNA+ individuals in Brazil in 2017 was 632,000 (0.31% of the population). Scale-up of treatment and diagnosis over time will be necessary in order to achieve WHO targets beginning in 2018. Direct costs (diagnostic, treatment and healthcare costs) are projected to increase significantly during the scale-up of treatment and diagnosis in the initial years of the intervention scenario, but then fall below the base case on an annual basis by 2025-2036, once HCV is eliminated, due to health sectors savings from the prevention of HCV liver-related morbidity and mortality.

Conclusion: Achieving the WHO targets is technically feasible in Brazil with a scale-up of treatment and diagnosis over time, beginning in 2018. However, elimination of hepatitis C requires policy changes to substantially scale-up prevention, screening and treatment of HCV, together with public health advocacy to raise awareness among affected populations and healthcare providers.

Citing Articles

Gestational syphilis in a tertiary health service in Paraná, Brazil: A case-control study.

Braz Pauli F, Junior V, Mesquita R, Wendt G, Fortes P, Harapan H PLoS One. 2024; 19(8):e0305525.

PMID: 39116054 PMC: 11309417. DOI: 10.1371/journal.pone.0305525.


Occurrence of hepatitis B and C virus infection in socioeconomic population strata from Recife, Pernambuco, Northeast Brazil.

Mariz C, Braga C, de Albuquerque M, Luna C, Salustiano D, Freire N Rev Bras Epidemiol. 2024; 27:e240033.

PMID: 38958369 PMC: 11221483. DOI: 10.1590/1980-549720240033.


Impact of sustained virologic response on glucose parameters among patients with chronic hepatitis C treated with direct-acting antivirals.

Benetti F, de Araujo A, de Maman Junior I, Coelho Borges Cheinquer C, Herz Wolff F, Cheinquer H Arch Endocrinol Metab. 2024; 68:e220480.

PMID: 38709148 PMC: 11081048. DOI: 10.20945/2359-4292-2022-0480.


Aspects that facilitate access to care for viral hepatitis: An evaluative research.

Gleriano J, Krein C, Chaves L Sao Paulo Med J. 2024; 142(4):e2023078.

PMID: 38477774 PMC: 10926966. DOI: 10.1590/1516-3180.2023.0078.R1.29112023.


Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation.

Diaz A, Witkin S, Almeida Neto C, Mendrone Junior A, Rocha V, Costa S Rev Inst Med Trop Sao Paulo. 2024; 66:e11.

PMID: 38324877 PMC: 10846481. DOI: 10.1590/S1678-9946202466011.


References
1.
Bruggmann P, Berg T, Ovrehus A, Moreno C, Brandao Mello C, Roudot-Thoraval F . Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014; 21 Suppl 1:5-33. DOI: 10.1111/jvh.12247. View

2.
da Silva N, Germano F, Mendoza-Sassi R, Seuanez H, Soares M, de Martinez A . Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil. Virol J. 2013; 10:167. PMC: 3680315. DOI: 10.1186/1743-422X-10-167. View

3.
Moreira Puga M, Bandeira L, Pompilio M, Croda J, de Rezende G, Dorisbor L . Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil. PLoS One. 2017; 12(1):e0169195. PMC: 5218405. DOI: 10.1371/journal.pone.0169195. View

4.
. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1211-1259. PMC: 5605509. DOI: 10.1016/S0140-6736(17)32154-2. View

5.
Mesquita F, Santos M, Benzaken A, Correa R, Cattapan E, Sereno L . The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy. BMC Public Health. 2016; 16(1):1132. PMC: 5094040. DOI: 10.1186/s12889-016-3784-4. View